Leaders in Oncology
"We are the best at what we do, because we have the best talent around."
Peter F. Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
"We are the best at what we do, because we have the best talent around."
Peter F. Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
As Global Oncology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson, Peter F. Lebowitz, M.D., Ph.D. is responsible for end-to-end discovery, development and life cycle advancement of the company’s robust oncology pipeline and portfolio. He leads a global team of scientists that bring together expertise in small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics, and immuno-oncology. Under Peter’s leadership, Janssen Oncology has achieved many noteworthy milestones including seven major product approvals in the last eight years for such first-in-class therapies as IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab) and ERLEADA® (apalutamide); seven U.S. Food and Drug Administration Breakthrough Therapy Designations; and tremendous, rapid growth within the group’s early development portfolio.
With a strategy focused on driving towards transformational therapies, Peter also successfully established an external innovation strategy to advance science and novel therapeutics in core disease areas, including hematologic malignancies, prostate cancer, immuno-oncology, and lung cancer. The combination of these efforts has led to more than 80 strategic oncology partnerships across the life sciences ecosystem and continues to distinguish Janssen as an industry leader and global oncology innovator.
Prior to his appointment as Global Oncology Therapeutic Area Head, Peter served as the Hematologic Malignancy Disease Area Leader within Janssen Research & Development. In this role, he had responsibility for creating and executing the scientific strategy to advance internal and externally-sourced discovery and development programs. Together with his team, Peter is recognized for building an industry-leading hematologic malignancy portfolio that has been foundational for scientific innovation and has progressed important therapeutics that have transformed patient care.
Before joining Janssen R&D, Peter held Vice President positions in Discovery and Early/Late-stage Clinical Development for GlaxoSmithKline where he successfully filed 10 Investigational New Drug applications and played a significant role in the global registration of three oncology medicines. During his tenure, he also directly led major programs from preclinical discovery through pivotal Phase 3 registration trials.
Prior to transitioning to the pharmaceutical industry, Peter served as an Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. There he established an independently funded translational and clinical research program and led numerous clinical research programs as a principal investigator. He also had the privilege of caring for many oncology patients during this time. Peter graduated magna cum laude from Harvard University, holds a master’s degree in Health Care Policy from Oxford University, and earned his medical degree and doctorate from the University of Pennsylvania School of Medicine. He completed his postgraduate clinical training in Internal Medicine at Duke University Medical Center and his Hematology/Oncology fellowship at the National Cancer Institute, National Institutes of Health. He has been board certified in Internal Medicine and Medical Oncology.
J.D. Alvarez, M.D., Ph.D. is Vice President, Oncology Diagnostics, for the Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he is responsible for developing and delivering diagnostic solutions that enable registration of compounds in the Oncology pipeline.
J.D. joined Janssen in 2009 as an Associate Director of Oncology Biomarkers and was responsible for establishing a molecular pathology laboratory to support the oncology biomarker investigations and strategies. He has held positions of increasing responsibility within Biomarkers, Translational Research and Clinical Research. He also represents Janssen on working groups within the Society for Immunotherapy of Cancer, the Association of Molecular Pathology and the Medical Device Innovation Consortium.
Prior to joining Janssen, J.D. served as a research associate at the University of Pennsylvania conducting independent National Institutes of Health grant-funded research on the function of circadian rhythms in disease physiology. He also held positions in both discovery research and oncology translational medicine at Nippon Roche K.K. and at Wyeth Research.
J.D. received his medical degree and his doctorate in Molecular Cell Biology from the Washington University School of Medicine in St. Louis, Missouri. He completed his residency and fellowship training through the University of Pennsylvania School of Medicine Department of Pathology and Laboratory Medicine. He is board certified in Anatomic Pathology and Molecular Genetic Pathology.
Yusri Elsayed, M.D., M.H.Sc., Ph.D. is the Vice President, Hematologic Malignancies Disease Area Stronghold Leader, Interim Head Early Development at Janssen Research & Development, LLC, and has worked in all stages of drug development, on both small and large molecules. Yusri has played an important role in the Hematologic Malignancies DAS since its inception and is a member of the core team and the business development team. He also played an important role in the diligence and in-licensing of recent Hematologic Malignancies DAS assets.
Yusri joined Janssen in 2005 as Medical Director/Project Physician. Since then, he has held positions of increasing responsibility, including Medical Leader and, most recently, Senior Director, Early Development Global Clinical Leader, leading the clinical development of several early-phase compounds for multiple myeloma and various B-cell malignancies.
Before joining Janssen, Yusri led early-development studies of oncology drugs, including small molecules and monoclonal antibodies, at Bristol-Myers Squibb. Prior to that, he was Assistant Professor of Medicine at the Cancer Institute of New Jersey and at the University of Medicine and Dentistry of New Jersey -Robert Wood Johnson Medical School, where he was a Principal Investigator on numerous Phase 1 and investigational therapeutics trials and authored numerous publications.
Yusri completed his residency in Internal Medicine at State University of New York at Stony Brook (Nassau University Medical Center program) and trained in Medical Oncology at the National Cancer Institute and in Hematology at the National Heart, Lung and Blood Institute, both of which are part of the National Institutes of Health, Bethesda, Maryland. He is board certified in medical oncology and in hematology. Yusri also earned a master’s degree in clinical research from Duke University in Durham, North Carolina and a doctorate from Kyushu University in Japan.
Joseph Erhardt, Ph.D. is Vice President, Oncology Scientific Partnership Strategy at Janssen Research & Development, LLC. In this role, he is responsible for strategic oversight and implementation of scientific partnership strategies for the Disease Area Strongholds in collaboration with Johnson & Johnson Innovation centers in the United States and Europe.
Joseph joined Janssen in 2012, serving as the Compound Development Team Leader for one of Janssen’s investigational compounds prior to his current position. Before joining Janssen, Joseph was the Head of Portfolio Strategy and Operations for Drug Discovery and Early Development at GlaxoSmithKline. In that role, he led the creation and implementation of strategic business planning for the unit.
In addition to roles in portfolio strategy, Joseph has led global oncology development teams in both early and late phases, including projects that he championed through rapid development paths into early pivotal studies, resulting in several approvals. Earlier in his career, he led a small molecule drug discovery laboratory and multiple oncology programs from late lead optimization through Investigational New Drug (IND) submission and early development.
Joseph received his doctorate in Pharmacology from the University of Pennsylvania in Philadelphia, Pennsylvania and conducted his postdoctoral research at SmithKline Beecham in the Department of Pharmacology.
Joseph Lehar, Ph.D., is Vice President, Data Sciences, Oncology, for the Janssen Pharmaceutical Companies of Johnson & Johnson.
Joseph leads a team responsible for creating unique and actionable medical insights using large and increasingly available datasets. Working in close collaboration with research scientists and other stakeholders, Joseph and his team apply data insights to inform decision-making, optimize innovation and identify best practices for applying data analytics in key areas of interest.
Joseph has global leadership responsibilities for a wide range of activities, including talent and capability development, training, resource deployment and supporting an organizational culture that promotes data-driven decision making across the Oncology Therapeutic Area, and together with partner teams.
Prior to joining Janssen, Joseph served as an Executive Director of Computational Biology at Merck Research Laboratories. Before then, he held leadership positions at Google/Verily where he built a computational biology capability for the business and at Novartis where he held a position as a Director of Bioinformatics for Oncology Translational Medicine. He also worked at CombinatoRx, a biotech company focused on drug combinations.
Joseph’s experience touches on systems biology, high-throughput screening, clinical investigations and digital phenotypes across multiple disease areas. He is also conducting research in these and other areas as an adjunct professor at Boston University. Joseph holds a Ph.D. in physics and originally pursued a career in astrophysics at Massachusetts Institute of Technology (MIT), Cambridge University and Harvard University.
Marco Gottardis, Ph.D. is Vice President and Prostate Cancer Disease Area Stronghold Leader for the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for maintaining and enhancing Janssen’s leadership in driving the strategy to discover and develop new therapeutics to treat and prevent prostate cancer.
Marco was an established leader in Oncology Discovery Research at Bristol-Myers Squibb (BMS) for 14 years with achievements spanning exploratory research to Investigational New Drug (IND) candidates. He led multiple scientific teams at BMS covering diverse target areas. He was a member of the Disease Sciences and Biologics Senior Leadership Team and served on the Oncology Early Development and Commercial Strategic Teams for Prostate and Melanoma. Marco has placed multiple discovery candidates into development and has successfully led Early Development Asset Teams that were responsible for progressing development candidates from IND to Phase 2 Proof of Concept.
Marco has 20 years of experience as a cancer research investigator in both biotech/large pharma and over 25 years’ experience in overall translational cancer research. He has had a role in the development of several drug approvals in his career. These include the seminal pre-clinical studies leading to the development of a treatment for breast cancer and the approval of selective estrogen receptor modulator, retinoid and retinoid X receptor drugs for cancer while he was a Senior Investigator at Ligand Pharmaceuticals, Inc., San Diego, California.
Jeffrey Infante, M.D. is Vice President, Early Clinical Development, Oncology, at Janssen.
Jeff is a world-renowned clinical investigator who has been involved in the development of many successful cancer drugs. He joined Janssen after a highly productive and successful decade in drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. At Sarah Cannon, Jeff served in many roles, including Director of the Drug Development Program, where he provided physician leadership to the Drug Development Unit in Florida, Oklahoma, Denver, and Nashville, which is one of the largest early phase clinical trial units for patients with advanced cancer in the country.
Prior to his tenure at Sarah Cannon, Jeff completed his fellowship in medical oncology at Johns Hopkins University School of Medicine. Over the course of his career, he has helped design and conduct many clinical trials ranging from first-in-human dosing through phase three registration trials. He has expertise with multiple novel treatments including molecularly targeted therapies, antibody drug conjugates and immuno-oncology agents.
Matthew Lorenzi, Ph.D. is Vice President, Lung Cancer Disease Area Stronghold Leader for the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, Matthew is responsible for the strategic direction of the lung cancer disease area from early drug discovery efforts through clinical development.
Prior to joining Janssen Research & Development, he was a senior oncology leader at Bristol-Myers Squibb, where he directed research teams focused on small molecule and biologics-based drug discovery. In addition, Matthew led an early clinical development team. Within these roles, he brought strong scientific leadership to successfully deliver multiple agents into and through clinical development.
Matthew also productively instituted several key initiatives including an oncology translational medicine research strategy and numerous academic collaborations supporting the clinical development of multiple assets. He served as a member of the Senior Leadership Team for Research, representing oncology drug discovery.
Matthew received his doctorate from the University of Miami, Florida, in Molecular Pharmacology and conducted his postdoctoral fellowship at the National Institutes of Health, Bethesda, Maryland, where he continued as a Senior Staff Fellow.
Michael Kalos, Ph.D., is Vice President, Janssen Immuno-Oncology and Oncology Cell Therapy, at Janssen. Michael has responsibility for further enhancing the scientific strategy required to deliver the Janssen portfolio of immuno-oncology and cell-based oncology therapeutics, and build a robust pipeline of next-generation compounds.
Michael joined Janssen from Eli Lilly where he served as Chief Scientific Officer, Cancer Immunobiology, and as a member of Lilly's research oncology leadership team. There, Michael had responsibility for establishing and overseeing an integrated immune-oncology strategy and program, which led to a pipeline of pre-clinical and clinical development assets. Michael is a graduate of the University of Minnesota Medical School where he received a degree in Microbiology with an emphasis in Genetics. He completed postdoctoral training at the Fred Hutchinson Cancer Research Center where he played a pioneering role in the development of genetic approaches to redirect lymphocyte specificity through transfer of T cell receptor chains. Following his tenure at the Fred Hutchinson Cancer Research Center, Michael moved to Corixa Corporation, a biotechnology company in Seattle and played key roles in the discovery and pre-clinical evaluation of novel cancer vaccines for prostate and lung cancer.
Prior to transitioning to the pharmaceutical industry, Michael spent 10 years in academia developing and translating immunotherapy strategies to treat disease, including at the University of Pennsylvania School of Medicine from 2008 through 2013, where he was critically involved in the translational and clinical development of gene-engineered T cell therapies. This work contributed to the foundational studies that established the potential of this therapeutic modality in oncology.
Michael is a recognized international key opinion leader in the fields of immunotherapy, T cell therapy, and biomarkers. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy; has been an invited speaker at national and international scientific meetings; served as a member of institutional and corporate scientific advisory boards; and is an active member of steering committees for international immunotherapy consortia and working groups.
Ian McCaffery, Ph.D., is Vice President and Head of Oncology Translational Research at Janssen Research and Development, LLC. Ian’s team is responsible for translational research, clinical biomarker discovery and development to support the Oncology Therapeutic Area pipeline. This includes dedicated disease area translational teams and cross-functional biomarker operations and bioinformatics teams.
Ian has more than 15 years of experience in the biotechnology industry, leading target, biomarker and companion diagnostic discovery and development programs in research and early/late-stage clinical development. He joined Janssen from Corvus Pharmaceuticals where he established and led the Discovery and Translational Research team focused on immuno-oncology discovery and translational research.
Prior to Corvus, Ian served as Global Head of Companion Diagnostic Development at Genentech, developing, clinically-validating and registering predictive and prognostic diagnostic markers across all therapeutic areas in the Genentech and Roche product development portfolios. Ian joined Genentech from Amgen having served in several roles with increasing responsibility, including as Head of the Oncology Biomarker Development Department in Medical Sciences with accountability for biomarker discovery and development for all research, early and late-stage development programs in oncology. Ian spent his early biotech career at Celera Genomics, using genomic and proteomic tools for target discovery research and drug development in oncology.
Ian received his Ph.D. in Biochemistry and Molecular Biology from the University of Leeds, United Kingdom and gained postdoctoral experience at the University of Virginia investigating mechanisms of gene regulation.
Wayne Rackoff, M.D. is Vice President, Clinical Oncology at Janssen Research & Development, LLC. His primary responsibilities include directing a project in conjunction with the Tufts Center for the Study of Drug Development in Massachusetts to develop a decision-making algorithm for advancing drugs from Phase 2 to Phase 3 in clinical development, modeling and implementing new approaches to patient accrual that will hasten the completion of late-stage oncology studies, and leading the clinical activities on major licensing and acquisition projects.
While at Janssen Research & Development, Wayne has worked as a Medical Affairs Physician, and as a Project Physician, Clinical Team Leader and Head of the Clinical Group in Oncology Research & Development.
Prior to joining Janssen Research & Development, Wayne served as a faculty member of the Indiana University School of Medicine in Indianapolis, and in a public hospital-based pediatric hematology-oncology practice in South Florida. He was also the Vice President of Early Development Oncology at GlaxoSmithKline.
Wayne holds a bachelor’s degree in English from Emory University, Atlanta, Georgia, and a master’s in political science and a medical degree from The University of North Carolina at Chapel Hill, where he completed his residency training in Pediatrics. He was a fellow in pediatric hematology-oncology at The Children’s Hospital of Philadelphia, Pennsylvania.
Sandra Rattray, Ph.D. leads the Oncology Therapeutic Area (TA) group within Global Regulatory Affairs (GRA) at Janssen Research & Development, LLC. This group provides leadership, management, strategic input and support to all projects and products across all stages of development within the oncology TA. In addition, Sandy manages the GRA Companion Diagnostic group, who provide regulatory leadership for companion diagnostic development across the Johnson & Johnson Family of Companies.
Prior to the Johnson & Johnson Family of Companies, Sandy had a 14-year career with Merck & Co, Inc., which spanned sales and marketing, drug discovery and regulatory affairs with Merck Research Labs (MRL). Before joining MRL Regulatory Affairs, she was a member of the MRL Department of Infectious Disease, where she held positions of increasing responsibility, culminating in Group Leader, New Lead Discovery.
Prior to joining Merck, Sandy held postdoctoral and faculty appointments in the Departments of Pharmacology and Therapeutics and Obstetrics and Gynecology, at the University of Florida. Her research throughout her academic career was focused on the discovery and development of anticancer agents.
Sandy received her undergraduate degree from Auckland University in New Zealand, as well as her master’s (first class honors) and doctorate in cellular and molecular biology.
Patrik Ringblom is the Global Commercial Strategy Leader for Oncology at Janssen Global Services responsible for setting and executing the oncology strategy, building disease area strongholds and developing deep therapeutic area expertise.
Prior to this role, Patrik was the Managing Director for the mid-size markets in Janssen Europe, Middle East, and Africa (EMEA) and a member of the European Leadership Team. He had responsibility for this complex region with different healthcare systems, market dynamics, distribution systems and cultures, and more than 30 countries including Sweden, Denmark, Finland, Norway, Belgium, the Netherlands, Greece, Israel, Poland, Czech Republic, Slovakia, Romania, Austria and Switzerland. He also played an important role in the design and implementation of Road 2010, a program that transformed the EMEA organization to meet evolving market demands.
Patrik holds a master’s in business administration and a bachelor’s degree in marketing and business administration, with a major in economics, from the University of Gothenburg in Sweden.
Craig Tendler, M.D. is Vice President, Late-Stage Development and Global Medical Affairs for Oncology, Hematology and Supportive Care at Janssen Research & Development, LLC. In this position, he is responsible for creating robust development plans and data generation activities for all products in the oncology portfolio, from late development through registration and lifecycle management. He works closely with Early Development and the Disease Area Strongholds to implement a seamless end-to-end oncology clinical research strategy that incorporates compelling science and addresses areas of high unmet medical need.
Prior to this role, Craig was Vice President of Medical Affairs for Tibotec Therapeutics and then Ortho-Biotech, where he led approximately 50 medical affairs professionals in lifecycle management and data generation for the Oncology and Virology franchises. He played a key role in addressing with United States and European Union health authorities the safe and appropriate use of a product for the treatment of anemia caused by chemotherapy, helping to shape public policy by conducting extensive research, education and risk minimization efforts.
Craig has overseen and coordinated 11 major drug approvals by national regulatory agencies, including five by the United States Food and Drug Administration (FDA). Most recently his team worked in collaboration with the FDA and the European Medicines Agency to secure the expeditious worldwide approval of Janssen’s treatment for metastatic castration-resistant prostate cancer. In 2013, Craig and his team were instrumental in achieving four FDA breakthrough designations for investigational drugs in development for various hematologic malignancies– in collaboration with our co-development partners.
Prior to joining Janssen Research & Development, Craig was the Vice President of Oncology Clinical Research and Chair of the Oncology Licensing Committee at the Schering-Plough Research Institute. In addition to his pharmaceutical industry experience, he has served as Assistant Professor of Pediatrics at the Mount Sinai School of Medicine in New York City and was a research fellow at the National Cancer Institute in Bethesda, Maryland.
Craig earned his undergraduate degree from Cornell University, Ithaca, New York and graduated from the Mount Sinai School of Medicine, New York City, with high honors. He is board certified in pediatrics with a subspecialty in hematology-oncology.
Debi Watson is Vice President, Business Development and Licensing, Janssen Pharmaceutical Companies of Johnson & Johnson, responsible for leading and executing transactions that support the Oncology Therapeutic Area. She oversees a group of professionals who play an active role in conducting diligence and executing transactions.
Prior to joining the Oncology team, Debi was responsible for the licensing activities of the Infectious Diseases and Vaccines Therapeutic Area. She joined Business Development and Licensing in 2005, where she developed the United States commercial strategy for licensing and acquisition opportunities within the Neuroscience Therapeutic Area and provided commercial input on pipeline assets.
Debi began her career within the Johnson & Johnson Family of Companies in 1991 and spent several years in Sales and Marketing, first as a sales representative in New England and then as a District Manager, before moving into Marketing in the Central Nervous System (CNS) Franchise, where she worked on several flagship brands for the company. She led the launch activities for a schizophrenia treatment that became one of the company’s most successful brands.
Debi received her bachelor’s degree from the University of Connecticut.